S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.48 (+0.30%)
AAPL   174.10 (-0.26%)
MSFT   290.01 (-0.45%)
META   174.55 (-0.17%)
GOOGL   119.90 (+0.29%)
AMZN   142.33 (+0.16%)
TSLA   908.01 (-0.44%)
NVDA   187.96 (+2.51%)
NIO   19.88 (-1.00%)
BABA   90.55 (+0.87%)
AMD   100.38 (+2.15%)
MU   62.95 (+2.16%)
T   18.43 (+0.05%)
CGC   3.80 (-6.40%)
F   16.15 (+0.75%)
GE   79.23 (-0.86%)
DIS   122.67 (-0.11%)
AMC   19.37 (-9.32%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.81 (+1.52%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.48 (+0.30%)
AAPL   174.10 (-0.26%)
MSFT   290.01 (-0.45%)
META   174.55 (-0.17%)
GOOGL   119.90 (+0.29%)
AMZN   142.33 (+0.16%)
TSLA   908.01 (-0.44%)
NVDA   187.96 (+2.51%)
NIO   19.88 (-1.00%)
BABA   90.55 (+0.87%)
AMD   100.38 (+2.15%)
MU   62.95 (+2.16%)
T   18.43 (+0.05%)
CGC   3.80 (-6.40%)
F   16.15 (+0.75%)
GE   79.23 (-0.86%)
DIS   122.67 (-0.11%)
AMC   19.37 (-9.32%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.81 (+1.52%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.48 (+0.30%)
AAPL   174.10 (-0.26%)
MSFT   290.01 (-0.45%)
META   174.55 (-0.17%)
GOOGL   119.90 (+0.29%)
AMZN   142.33 (+0.16%)
TSLA   908.01 (-0.44%)
NVDA   187.96 (+2.51%)
NIO   19.88 (-1.00%)
BABA   90.55 (+0.87%)
AMD   100.38 (+2.15%)
MU   62.95 (+2.16%)
T   18.43 (+0.05%)
CGC   3.80 (-6.40%)
F   16.15 (+0.75%)
GE   79.23 (-0.86%)
DIS   122.67 (-0.11%)
AMC   19.37 (-9.32%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.81 (+1.52%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.48 (+0.30%)
AAPL   174.10 (-0.26%)
MSFT   290.01 (-0.45%)
META   174.55 (-0.17%)
GOOGL   119.90 (+0.29%)
AMZN   142.33 (+0.16%)
TSLA   908.01 (-0.44%)
NVDA   187.96 (+2.51%)
NIO   19.88 (-1.00%)
BABA   90.55 (+0.87%)
AMD   100.38 (+2.15%)
MU   62.95 (+2.16%)
T   18.43 (+0.05%)
CGC   3.80 (-6.40%)
F   16.15 (+0.75%)
GE   79.23 (-0.86%)
DIS   122.67 (-0.11%)
AMC   19.37 (-9.32%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.81 (+1.52%)
NASDAQ:SWAV

ShockWave Medical - SWAV Stock Forecast, Price & News

$296.68
+13.22 (+4.66%)
(As of 08/18/2022 03:59 PM ET)
Add
Compare
Today's Range
$283.67
$298.63
50-Day Range
$156.73
$296.82
52-Week Range
$113.36
$301.00
Volume
16,371 shs
Average Volume
576,526 shs
Market Capitalization
$10.62 billion
P/E Ratio
203.21
Dividend Yield
N/A
Price Target
$248.17

ShockWave Medical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
15.7% Downside
$248.17 Price Target
Short Interest
Healthy
5.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.54mentions of ShockWave Medical in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$28.53 M Sold Last Quarter
Proj. Earnings Growth
33.07%
From $2.57 to $3.42 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

378th out of 1,119 stocks

Surgical & Medical Instruments Industry

36th out of 111 stocks

SWAV stock logo

About ShockWave Medical (NASDAQ:SWAV) Stock

ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Canaccord Genuity Group boosted their price objective on ShockWave Medical from $232.00 to $256.00 and gave the stock a "buy" rating in a research note on Tuesday, August 9th. Piper Sandler increased their price objective on ShockWave Medical from $245.00 to $278.00 and gave the company an "overweight" rating in a research note on Tuesday, August 9th. Wells Fargo & Company increased their price objective on ShockWave Medical from $176.00 to $255.00 and gave the company an "overweight" rating in a research note on Tuesday, August 9th. Finally, Morgan Stanley increased their price objective on ShockWave Medical from $201.00 to $255.00 and gave the company an "equal weight" rating in a research note on Tuesday, August 9th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $249.57.

ShockWave Medical Trading Up 3.8 %

Shares of NASDAQ:SWAV traded up $10.89 during mid-day trading on Thursday, reaching $294.35. 5,348 shares of the company's stock were exchanged, compared to its average volume of 576,526. The firm has a market capitalization of $10.53 billion, a price-to-earnings ratio of 194.15 and a beta of 1.24. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.41 and a current ratio of 5.32. ShockWave Medical has a 52-week low of $113.36 and a 52-week high of $301.00. The company's 50-day moving average is $209.08 and its 200-day moving average is $184.42.

ShockWave Medical (NASDAQ:SWAV - Get Rating) last announced its earnings results on Monday, August 8th. The company reported $0.68 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.25. ShockWave Medical had a return on equity of 21.25% and a net margin of 15.11%. The company had revenue of $120.70 million during the quarter, compared to analysts' expectations of $107.51 million. During the same period last year, the business posted ($0.01) EPS. ShockWave Medical's revenue for the quarter was up 115.5% on a year-over-year basis. Analysts expect that ShockWave Medical will post 2.57 EPS for the current fiscal year.

Insider Activity at ShockWave Medical

In related news, CFO Dan Puckett sold 1,350 shares of the firm's stock in a transaction dated Friday, May 20th. The stock was sold at an average price of $161.38, for a total transaction of $217,863.00. Following the completion of the transaction, the chief financial officer now directly owns 41,048 shares in the company, valued at approximately $6,624,326.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other ShockWave Medical news, CFO Dan Puckett sold 1,350 shares of the stock in a transaction dated Friday, May 20th. The stock was sold at an average price of $161.38, for a total value of $217,863.00. Following the sale, the chief financial officer now owns 41,048 shares of the company's stock, valued at approximately $6,624,326.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Antoine Papiernik sold 50,000 shares of the firm's stock in a transaction dated Friday, August 12th. The stock was sold at an average price of $288.11, for a total value of $14,405,500.00. Following the sale, the director now directly owns 12,251 shares in the company, valued at approximately $3,529,635.61. The disclosure for this sale can be found here. Insiders sold 111,112 shares of company stock worth $28,534,938 in the last three months. 3.90% of the stock is owned by company insiders.

Receive SWAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ShockWave Medical and its competitors with MarketBeat's FREE daily newsletter.

SWAV Stock News Headlines

ShockWave Medical (NASDAQ:SWAV) Price Target Raised to $256.00
4 Analysts Have This to Say About ShockWave Medical
Why ShockWave Medical Stock Is Soaring Today
LHC Group (LHCG) Q2 Earnings & Revenues Miss Estimates
See More Headlines
Receive SWAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ShockWave Medical and its competitors with MarketBeat's FREE daily newsletter.

SWAV Company Calendar

Last Earnings
8/08/2022
Today
8/18/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SWAV
Fax
N/A
Employees
657
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$248.17
High Stock Price Forecast
$278.00
Low Stock Price Forecast
$190.00
Forecasted Upside/Downside
-16.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-9,140,000.00
Pretax Margin
15.43%

Debt

Sales & Book Value

Annual Sales
$237.15 million
Book Value
$8.52 per share

Miscellaneous

Free Float
34,396,000
Market Cap
$10.62 billion
Optionable
Not Optionable
Beta
1.24

Key Executives














SWAV Stock - Frequently Asked Questions

Should I buy or sell ShockWave Medical stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ShockWave Medical in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SWAV shares.
View SWAV analyst ratings
or view top-rated stocks.

What is ShockWave Medical's stock price forecast for 2022?

7 Wall Street analysts have issued 12-month price objectives for ShockWave Medical's shares. Their SWAV share price forecasts range from $190.00 to $278.00. On average, they expect the company's share price to reach $248.17 in the next year. This suggests that the stock has a possible downside of 12.5%.
View analysts price targets for SWAV
or view top-rated stocks among Wall Street analysts.

How have SWAV shares performed in 2022?

ShockWave Medical's stock was trading at $178.33 on January 1st, 2022. Since then, SWAV stock has increased by 59.0% and is now trading at $283.46.
View the best growth stocks for 2022 here
.

When is ShockWave Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our SWAV earnings forecast
.

How were ShockWave Medical's earnings last quarter?

ShockWave Medical, Inc. (NASDAQ:SWAV) announced its quarterly earnings results on Monday, August, 8th. The company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.25. The business earned $120.70 million during the quarter, compared to analysts' expectations of $107.51 million. ShockWave Medical had a net margin of 15.11% and a trailing twelve-month return on equity of 21.25%. The company's quarterly revenue was up 115.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.01) earnings per share.

What guidance has ShockWave Medical issued on next quarter's earnings?

ShockWave Medical updated its FY 2022 earnings guidance on Tuesday, August, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $465.00 million-$475.00 million, compared to the consensus revenue estimate of $448.64 million.

What is Doug Godshall's approval rating as ShockWave Medical's CEO?

8 employees have rated ShockWave Medical Chief Executive Officer Doug Godshall on Glassdoor.com. Doug Godshall has an approval rating of 89% among the company's employees.

What other stocks do shareholders of ShockWave Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ShockWave Medical investors own include NVIDIA (NVDA), Walt Disney (DIS), Block (SQ), Trade Desk (TTD), Salesforce (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA).

When did ShockWave Medical IPO?

(SWAV) raised $75 million in an initial public offering on Thursday, March 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is ShockWave Medical's stock symbol?

ShockWave Medical trades on the NASDAQ under the ticker symbol "SWAV."

Who are ShockWave Medical's major shareholders?

ShockWave Medical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (8.98%), FMR LLC (8.62%), State Street Corp (3.15%), JPMorgan Chase & Co. (3.13%), Macquarie Group Ltd. (3.12%) and Artisan Partners Limited Partnership (1.95%). Insiders that own company stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frank T Watkins, Frank T Watkins, Frederic H Moll, Isaac Zacharias, Kurt F Gallo, Laura Francis, Sofinnova Capital Vii Fcpr and Trinh Phung.
View institutional ownership trends
.

How do I buy shares of ShockWave Medical?

Shares of SWAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ShockWave Medical's stock price today?

One share of SWAV stock can currently be purchased for approximately $283.46.

How much money does ShockWave Medical make?

ShockWave Medical (NASDAQ:SWAV) has a market capitalization of $10.15 billion and generates $237.15 million in revenue each year. The company earns $-9,140,000.00 in net income (profit) each year or $1.46 on an earnings per share basis.

How many employees does ShockWave Medical have?

The company employs 657 workers across the globe.

How can I contact ShockWave Medical?

ShockWave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The official website for the company is www.shockwavemedical.com. The company can be reached via phone at (510) 279-4262 or via email at investors@shockwavemedical.com.

This page (NASDAQ:SWAV) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.